Synvisc - instructions for use, reviews, analogs and forms of release (injections in ampoules of a liquid prosthesis for intra-articular injections in a 2 ml syringe, 1 to 6 ml) for the treatment of arthrosis in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Synwisk. Comments of visitors of the site - consumers of this medication, as well as opinions of specialists in the use of Synvisc in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Synvisc in the presence of existing structural analogues.Use for the treatment of arthrosis of the knee, hip, shoulder, ankle joints and the replacement of synovial fluid in adults, children, as well as during pregnancy and lactation. Composition of liquid prosthesis for intraarticular injection.

Synwisk - sterile, pyrogen-free, viscoelastic fluid containing gilanes. Gilans are derivatives of hyaluronate (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglycosamine and sodium glucuronate. The average molecular weight of gilan A is about 6 million Da, and Gilan B is a hydrated gel.

Synvisc is a biological analog of hyaluronate. Hyaluronate is a component of the synovial fluid, which determines its viscoelastic properties.

Synvisc temporarily replaces and replenishes the synovial fluid; is effective in patients at any stage of joint pathology; is most effective in patients with active and regular load on the affected joint; achieves its therapeutic effect by restoring viscosity, thereby restoring the rheological properties of the synovial fluid and the physiological properties of the tissues of the joint affected by osteoarthritis.

Recovery of viscosity is a treatment aimed at reducing pain and discomfort, and also providing more extensive movement of joints. Studies have shown that Synvisc protects cartilage cells from certain physical and chemical damage.

Synvisc is intended only for intraarticular administration by a physician for the treatment of pain caused by osteoarthrosis of the knee, hip, ankle or shoulder joint.

Composition

Gilan (Hylan G-F 20) + excipients.

Indications

• osteoarthrosis of the hip, knee, ankle, shoulder joints.

Forms of release

Fluid in a 2 ml syringe (injections in ampoules for intra-articular injection) (Prosthesis of synovial fluid Synvisc).

Fluid in syringe glass 6 ml (Prosthesis of synovial fluid Synvisc 1 (one)).

Instructions for use and how to use them

Prosthesis of synovial fluid Synvisc

Intra-articular. Synvisc should be administered at room temperature.

Before each injection Synvisc should be removed synovial fluid or intra-articular exudate.

You can not use Synvisc in case the package is opened or damaged.

To remove the syringe from the blister (or case), it should be taken by the body, without touching the piston rod.

Synvisc should be administered in strict accordance with the rules of asepsis, therefore it is necessary to observe the appropriate precautions when removing the protective cap from the syringe.

It is necessary to turn the cap before removing it, in order to minimize leaks of the preparation.

The appropriate size (18-22) and the length of the needle should be used, depending on the joint to which the injection is intended.

To prevent leakage of the drug during administration, it is necessary to hold the needle in close contact with the syringe.

Do not twist and apply excessive force when fixing the needle or removing the cap, tk. this can lead to breakage of the tip of the syringe.

Do not re-sterilize Synvisc.

To introduce Synvisc strictly into the joint space. If necessary, use the fluoroscopic determination of the direction of injection, especially when injected into the hip and shoulder joint.

The contents of the syringe are for single use only.

When fluoroscopy is used to determine the direction of injection, ionic ornonionic contrast medium. For every 2 ml of Synvisc, no more than 1 ml of contrast medium should be used.

Recommendations for use

The mode of use of Synvisc depends on the joint to which the injection is made.

Knee osteoarthritis: recommended treatment regimen - 3 injections at the knee joint with an interval of 1 week between injections. To achieve maximum effect, the appointment of all 3 injections is mandatory. The maximum recommended dosage is 6 injections for 6 months with a minimum interval of 4 weeks between dosage regimens.

Osteoarthrosis of the hip, ankle, shoulder joint: the recommended treatment regimen is 1 injection. However, if an adequate symptomatic improvement is not achieved after the injection, a second injection is recommended. Clinical evidence suggests that patients benefit most from the second injection, when it is administered 1-3 months after the first.

The effect of Synvisc only affects the affected joint. Synvisc does not have a common effect. Typically, the duration of Synvisca in patients who responded to treatment,was up to 26 weeks, although shorter and longer periods were observed. However, prospective clinical data of patients with knee osteoarthritis demonstrated efficacy of treatment up to 52 weeks after one course of 3 injections of Synvisc.

Prosthesis of synovial fluid Synvisc 1 (one-уан)

Recommended mode of application Synvisca 1 - 1 injection into the knee joint. Repeat injection, if necessary, can be administered 6 months after the first.

Before Synvisca 1 injection, the synovial fluid or exudate should be removed.

Synviscus 1 should be administered at room temperature, in strict accordance with aseptic procedures, especially when removing the protective cap from the syringe.

Synvisc 1 should be injected strictly into the synovial space, using fluoroscopy as necessary to determine the direction of injection.

When using fluoroscopy, an ionic or non-ionic contrast agent may be used to determine the direction of injection. For every 2 ml of Synvisc 1, no more than 1 ml of contrast medium should be used.

Use the appropriate length and size (18-20) of the needle.

Side effect

• short-term pain and / or swelling in the area of ​​injection;
• the appearance of intra-articular exudation;
• rash;
• hives;
• itching;
• nausea;
• headache;
• dizziness;
• chills;
• muscle cramps;
• paresthesia;
• peripheral edema (including on the face);
• weakness;
• difficulty breathing;
• redness of the skin.

The postmarketing experience of using Synvisc showed that in some cases exudation can be significant and cause a longer pain syndrome. It is necessary to perform joint puncture and remove exudate followed by its analysis to exclude infection and microcrystalline arthropathies. Usually, the reaction goes without a trace for several days. The presence of such reactions does not affect the efficiency. In clinical trials, intraarticular infections were rarely seen.

In controlled clinical studies of Synvisc, there was no statistically significant difference in the number or types of systemic side effects between the group of patients receiving the drugs and the control group. The frequency and types of side effects were similar in the group of patients receiving Synvisc and the group of patients receiving placebo.

Contraindications

• presence of venous or lymphatic stasis on the side of the affected joint;
• presence of infection or severe inflammation of the joint, as well as the presence of signs of skin infection in the immediate vicinity of the injection site;
• Do not use for intravascular injection;
• can not be administered extraarticularly, incl. in synovial tissue or joint capsule (possibly the occurrence of local adverse reactions);
• Do not use together with disinfectants for skin treatment containing quaternary ammonium salts (in their presence, it is possible the precipitation of hyaluronate);
• pregnancy;
• lactation;
• children under 18 years of age (not enough clinical data).

Application in pregnancy and lactation

The use of Synvisc and Synvisc 1 is contraindicated in pregnancy and lactation (there are not enough clinical data for use in this group of patients).

Use in children

Contraindicated in children and adolescents under the age of 18 years (not enough clinical data for use in this group of patients).

special instructions

Do not administer the drug if there is a significant intra-articular effusion.

As after any invasive procedure in the joint, after the injection the patient is recommended to adhere to a gentle regimen, gradually restoring the usual activity for several days.

Drugs have not been studied in pregnant women, children and adolescents under 18 years of age.

Preparations contain a small amount of chicken protein, so care should be taken when treating patients with hypersensitivity to chicken protein.

The contents of the syringe are for single use only.

Do not use Synvisc if the package is opened or damaged.

Removing the syringe from the blister, it should be held by the body, without touching the piston.

Re-sterilization Synvisc is not allowed.

Drug Interactions

Not noted.

Analogues of the medicine Synvisc

Structural analogs for the active substance:

• Atri Ing;
• Gialgan;
• Gilan;
• Gilart;
• Gilart Forte;
• Gou He;
• Ostenil;
• Ostanenil mini;
• Provis;
• Rusvik;
• Synvisc 1;
• A syncope;
• Fermatron;
• Hi-Flex;
• Healon Endocut;
• Hualubriks;
• Estelis Basik.

Analogues on the curative effect (agents for the treatment of arthrosis):

• Alflutop;
• Amelotex;
• Apizarthron;
• Arkoxy;
• Artradol;
• Arthrosan;
• Arthrosylen;
• Arthromax;
• Arthroflex;
• Arthrofoon;
• Aertal;
• Voltaren;
• Voltaren Emulgel;
• Gialrypayer;
• Hydrocortisone;
• Dexalgin;
• Diklak;
• Diqlovit;
• Diclosan forte;
• Dicloran plus;
• Diclofenac;
• Dylax;
• Dimexide;
• Deep Relief;
• Diskus compositum;
• Dolgit;
• Durogesic;
• Indomethacin;
• Inoltra;
• Ketonal;
• Ketoprofen;
• Ketorol;
• Xsefokam;
• Adhesive plaster medical Nanoplast forte;
• Longidase;
• Meloksam;
• Meloksikam;
• Midokalm;
• Movalis;
• Naisylate;
• Nyz;
• Naklofen;
• Neurodiclavitis;
• Nimesil;
• Nimesulide;
• Piroxicam;
• Rapten Duo;
• Rheumatic Gel;
• Sirdalud;
• Structum;
• Teraflex;
• Teraflex Advance;
• Fendivia;
• Finalal;
• Flamadex;
• Flamax;
• Hondrogaard;
• Chondroitin;
• Chondroxide;
• Chondroxide gel;
• Chondroxide ointment;
• Celebrex;
• The purpose of T;
• Elbon;
• Espoo.

Similar medicines:

Other medicines: